Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Isabella M. Frigerio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7616-4226; OpenAlex author ID A5019756541. Sources: OpenAlex.

Their work

Papers
38 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
155
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: 5 papers · 2026: 6 papers

Papers 38

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  3. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  4. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  5. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  6. Gut Microbiome Compositional and Functional Signatures Associated with Chemotherapy Response in Pancreatic Ductal Adenocarcinoma: An Exploratory Cohort Study. Co-author DOI 10.3390/metabo16100720↗
  7. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  8. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  9. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  10. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  11. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/cancers17091437↗
  12. Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2024.09.010↗
  13. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  14. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  15. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  16. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2023.02.005↗
  17. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  18. Telemedicine and Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1089/tmj.2022.0140↗
  19. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  20. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Co-author DOI 10.1055/a-1178-0474↗
  21. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  22. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. Co-author DOI 10.3390/cells11213340↗
  23. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  24. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  25. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02509-3↗
  26. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  27. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  28. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  29. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  30. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  31. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  32. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗
  33. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Co-author DOI 10.1007/s13304-016-0385-9↗
  34. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Co-author DOI 10.1155/2016/4508376↗
  35. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  36. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Co-author DOI 10.1159/000375323↗
  37. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. Co-author DOI 10.1007/s00534-013-0613-3↗
  38. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.8789↗

Closest collaborators

The 25 strongest of 155 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giovanni Butturini · 23 shared papers, 2015–2026 · strength 3.15
  2. Alessandro Giardino · 18 shared papers, 2012–2026 · strength 2.07
  3. Roberto Salvia · 17 shared papers, 2012–2026 · strength 1.55
  4. Roberto Girelli · 15 shared papers, 2012–2026 · strength 1.50
  5. Paolo Regi · 11 shared papers, 2013–2026 · strength 1.23
  6. Claudio Bassi · 16 shared papers, 2012–2024 · strength 1.21
  7. Filippo Scopelliti · 9 shared papers, 2017–2026 · strength 1.10
  8. Salvatore Paiella · 12 shared papers, 2015–2026 · strength 1.06
  9. Erica Pizzocaro · 4 shared papers, 2023–2026 · strength 1.04
  10. Giuseppe Malleo · 8 shared papers, 2017–2025 · strength 0.78
  11. Mirko D’Onofrio · 9 shared papers, 2015–2022 · strength 0.72
  12. Massimo Falconi · 5 shared papers, 2019–2026 · strength 0.60
  13. Marzia Tripepi · 3 shared papers, 2023–2024 · strength 0.58
  14. Gaya Spolverato · 3 shared papers, 2023–2024 · strength 0.55
  15. Quoc Riccardo Bao · 3 shared papers, 2023–2024 · strength 0.55
  16. Roberta Vella · 2 shared papers, 2025–2026 · strength 0.53
  17. Giulia Martina Cavestro · 3 shared papers, 2019–2026 · strength 0.38
  18. Silvia Carrara · 3 shared papers, 2019–2026 · strength 0.38
  19. Gabriele Capurso · 3 shared papers, 2019–2026 · strength 0.38
  20. Paolo Pederzoli · 3 shared papers, 2016–2026 · strength 0.38
  21. Erica Secchettin · 3 shared papers, 2018–2026 · strength 0.37
  22. Thilo Hackert · 3 shared papers, 2020–2025 · strength 0.35
  23. Marc G. Besselink · 3 shared papers, 2020–2025 · strength 0.35
  24. Riccardo De Robertis · 3 shared papers, 2016–2022 · strength 0.31
  25. Valentina Arcangeli · 2 shared papers, 2024–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.